174 related articles for article (PubMed ID: 22450901)
21. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
22. Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies.
Hershman DL; Neugut AI; Shim JJ; Glied S; Tsai WY; Wright JD
J Oncol Pract; 2014 Jul; 10(4):264-9. PubMed ID: 24737875
[TBL] [Abstract][Full Text] [Related]
23. Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.
Hendrick F; Davidoff AJ; Zeidan AM; Gore SD; Baer MR
Medicare Medicaid Res Rev; 2014; 4(4):. PubMed ID: 25485173
[TBL] [Abstract][Full Text] [Related]
24. The effect for oncology of the national coverage determination for erythropoiesis-stimulating agents.
Jorgenson JA
Manag Care Interface; 2008 Jul; 21(1):7-8. PubMed ID: 18727312
[No Abstract] [Full Text] [Related]
25. Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories.
Chan Q; Chan A
J Oncol Pharm Pract; 2011 Dec; 17(4):350-9. PubMed ID: 20659968
[TBL] [Abstract][Full Text] [Related]
26. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
Hershman DL; Buono DL; Malin J; McBride R; Tsai WY; Neugut AI
J Natl Cancer Inst; 2009 Dec; 101(23):1633-41. PubMed ID: 19903808
[TBL] [Abstract][Full Text] [Related]
27. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?
Shander A; Spence RK; Auerbach M
Transfusion; 2010 Mar; 50(3):719-32. PubMed ID: 19919555
[TBL] [Abstract][Full Text] [Related]
28. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.
Lai Y; Ye Z; Civan JM; Wang C; Cristofanilli M; Mu Z; Austin L; Palazzo JP; Myers RE; Yang H
Breast Cancer Res Treat; 2015 Sep; 153(2):407-16. PubMed ID: 26264468
[TBL] [Abstract][Full Text] [Related]
29. An epidemiological review of red cell transfusions in cancer chemotherapy.
Skillings JR; Rogers-Melamed I; Nabholtz JM; Sawka C; Gwadry-Sridhar F; Moquin JP; Rubinger M; Ganguly P; Burnell M; Shustik C; Dryer D; McLaughlin M; White D
Cancer Prev Control; 1999 Jun; 3(3):207-12. PubMed ID: 10474769
[TBL] [Abstract][Full Text] [Related]
30. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey.
Ray-Coquard I; Morère JF; Scotté F; Cals L; Antoine EC
Adv Ther; 2012 Feb; 29(2):124-33. PubMed ID: 22314432
[TBL] [Abstract][Full Text] [Related]
31. Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.
Xu L; Xu H; Cannavale K; Sattayapiwat O; Rodriguez R; Page JH; Chao C
Support Care Cancer; 2016 Jul; 24(7):2989-98. PubMed ID: 26872791
[TBL] [Abstract][Full Text] [Related]
32. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
33. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea.
Kang RY; Lee J; Lee YH; Lee HS; Jeong JH; Lee YJ
Int J Clin Pharm; 2012 Aug; 34(4):651-7. PubMed ID: 22729393
[TBL] [Abstract][Full Text] [Related]
34. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
Szucs TD; Blank PR; Schwenkglenks M; Aapro M
Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
[TBL] [Abstract][Full Text] [Related]
35. Cancer-related anaemia management in the 21st century.
Pronzato P
Cancer Treat Rev; 2006; 32 Suppl 2():S1-3. PubMed ID: 16725269
[TBL] [Abstract][Full Text] [Related]
36. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
Costiniuk CT; Camacho F; Cooper CL
Clin Infect Dis; 2008 Jul; 47(2):198-202. PubMed ID: 18532889
[TBL] [Abstract][Full Text] [Related]
37. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.
Lafeuille MH; Bailey RA; Vekeman F; Kilpatrick BS; Senbetta M; Piech CT; Lefebvre P
Consult Pharm; 2010 Aug; 25(8):493-500. PubMed ID: 20736158
[TBL] [Abstract][Full Text] [Related]
38. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
39. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
40. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]